Thera-SAbDab

RAMUCIRUMAB

>   Structural Summary
TherapeuticRamucirumab
TargetKDR
Heavy ChainEVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVTDAFDIWGQGTMVTVSS
Light ChainDIQMTQSPSSVSASIGDRVTITCRASQGIDNWLGWYQQKPGKAPKLLIYDASNLDTGVPSRFSGSGSGTYFTLTISSLQAEDFAVYFCQQAKAFPPTFGGGTKVDIK
100% seqID Fv Structure3s34 [Fvs: HL], 3s36 [Fvs: HL], 3s37 [Fvs: HL]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)Active
Recorded Developmental TechnologyDyax Human Phage Display
INN Year Proposed2008
INN Year Recommended2009
Companies InvolvedDyax, AstraZeneca, Dana-Farber Cancer Institute, Eli Lilly, Merck Sharp & Dohme, University of Texas M. D. Anderson Cancer Center, Washington University School of Medicine
Conditions ApprovedColorectal cancer, Gastric cancer, Non-small cell lung cancer, Liver cancer
Conditions ActiveOesophageal cancer, Urogenital cancer, Biliary cancer, Carcinoid tumour, Solid tumours, Pancreatic cancer
Conditions DiscontinuedBreast cancer, Malignant melanoma, Ovarian cancer, Prostate cancer, Renal cell carcinoma
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]